Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants Late-breaking data presented at 9th ESWI Influenza Conference in Valencia ...

This updated vaccine is designed to combat the JN.1 lineage of Omicron subvariants for adults aged 18 and over, marking it as the first commercially available sa-mRNA COVID-19 vaccine of its kind.

Unlike previous COVID-19 vaccines, the public will have to pay for these, although most insurance companies plan to cover some or all of the cost. By Michael Karlis on Fri, Sep 15, 2023 at 4:41 pm ...